 |
 |
 |
 |
 |
 |
Predictive Biosciences to Participate in Panel LEXINGTON, Mass. – June 10, 2008 – Predictive Biosciences, an emerging molecular diagnostics company developing non-invasive diagnostic products for informed cancer management™, today announced that Peter Klemm, Ph.D., president and chief executive officer, has been selected to participate in a breakout session at the BIO 2008 International Convention on Tuesday, June 17, 2008 at 10:15 a.m. (PT) taking place at the San Diego Convention Center in Room 27 AB. The session titled, “Driving Adoption of Tomorrow’s Cancer Diagnostics in Today’s Clinical Practice,” will include an overview of the rapidly growing field of next-generation molecular diagnostics with potential for cancer management. Participants will discuss the challenges and approaches to validating clinically useful molecular diagnostic assays and integrating them into clinical practice. The session will be led by Mara Aspinall, chairman of the Board of Directors for Predictive Biosciences and former president, Genzyme Genetics. “We are looking forward to participating in this session at BIO and discussing the need that exists for highly accurate and convenient diagnostic tools,” stated Dr. Klemm. “Predictive Biosciences’ novel urine-based tests in development employ patented and proprietary protein biomarkers and clinical algorithms, which will enable physicians to reliably determine the presence or absence of cancer. Ultimately we believe our innovative tests will allow for individualized diagnostics and clinical interventions to improve the management of cancer patients.” About Predictive Biosciences Leveraging its portfolio of patented biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management™. Predictive Biosciences’ tests will enable physicians to reliably determine the presence or absence of cancer. This information, incorporated into current standard clinical practice, should lead to more effective utilization of existing diagnostic tools and ultimately better outcomes for patients. Predictive Biosciences’ first assays are designed to detect urinary biomarkers fundamentally associated with the physiological changes resulting from cancer development and progression. The initial focus for these tests will be the growing cancer survivor population and the large number of individuals undergoing clinical workups for cancer. Predictive Biosciences was launched in 2006 and is privately funded by Highland Capital Partners and Flybridge Capital Partners (formerly IDG Ventures Atlantic). For more information and partnership inquiries, visit Predictive Biosciences’ website at www.predictivebiosci.com. ###
Contacts: Sheryl Seapy
|
Download this Press Release as a pdf file.